VivoSeq
Oncology

HER2-Positive Metastatic Breast Cancer

1

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

HER2-positive Metastatic Breast Cancer is an early-stage landscape with 1 program across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Trastuzumab Emtansine

Seoul National University Bundang Hospital

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Recruiting·AAbramson Cancer Center at Penn Medicine·N/A·NCT06551116·200 enrolled
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Recruiting·JJules Bordet Institute·Phase 2·NCT06595563·87 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)